Your browser doesn't support javascript.
loading
Incident Cancer Risk of Patients with Prevalent Type 2 Diabetes Mellitus in Hungary (Part 2).
Abonyi-Tóth, Zsolt; Rokszin, György; Süto, Gábor; Fábián, Ibolya; Kiss, Zoltán; Jermendy, György; Kempler, Péter; Lengyel, Csaba; Wittmann, István; Molnár, Gergo A.
Affiliation
  • Abonyi-Tóth Z; RxTarget Ltd., 5000 Szolnok, Hungary.
  • Rokszin G; Department of Biostatistics, University of Veterinary Medicine, 1078 Budapest, Hungary.
  • Süto G; RxTarget Ltd., 5000 Szolnok, Hungary.
  • Fábián I; Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, 7624 Pécs, Hungary.
  • Kiss Z; RxTarget Ltd., 5000 Szolnok, Hungary.
  • Jermendy G; Department of Biostatistics, University of Veterinary Medicine, 1078 Budapest, Hungary.
  • Kempler P; Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, 7624 Pécs, Hungary.
  • Lengyel C; Department of Internal Medicine, Bajcsy-Zsilinszky Hospital, 1106 Budapest, Hungary.
  • Wittmann I; Department of Medicine and Oncology, Faculty of Medicine, Semmelweis University, 1089 Budapest, Hungary.
  • Molnár GA; Department of Internal Medicine, University of Szeged, 6720 Szeged, Hungary.
Cancers (Basel) ; 16(13)2024 Jun 29.
Article in En | MEDLINE | ID: mdl-39001476
ABSTRACT
(1)

Background:

Among the chronic complications of type 2 diabetes mellitus, cancer has become the leading cause of death in several countries. Our objective was to determine whether prevalent type 2 diabetes mellitus is associated with a higher incidence of cancer. (2)

Methods:

This study comprised a nationwide analysis conducted in Hungary. The study population was divided into two groups a type 2 diabetes mellitus group vs. a non-diabetic group. The primary outcome was the risk related to overall cancer incidence; a key secondary outcome was the overall incidence of cancer in distinct study years; and a further outcome was the annual percent changes. (3)

Results:

The odds ratio related to the overall incidence of cancer was 2.50 (95% confidence interval 2.46-2.55, p < 0.0001) in patients with diabetes as related to non-diabetic controls. The odds ratio was higher in males than in females [ORmales 2.76 (2.70-2.82) vs. ORfemales 2.27 (2.22-2.33), p < 0.05 for male-to-female comparison]. The annual cancer incidence rate declined in non-diabetic controls, but not in patients with diabetes [-1.79% (-2.07--1.52%), p < 0.0001] vs. -0.50% (-1.12-+0.10%), p = 0.0991]. Several types of cancer showed a decreasing tendency in non-diabetic controls, but not in patients with type 2 diabetes. (4)

Conclusions:

Type 2 diabetes is associated with a higher risk of cancer. While the cancer incidence decreased for non-diabetic individuals with time, it remained unchanged in patients with T2DM.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2024 Document type: Article Affiliation country: Country of publication: